Oxford Biomedica: CTL019 And Product Out-Licensing To Drive 2017
Edison | Apr 05, 2017 04:40AM ET
We expect Oxford Biomedica’s (LON:OXB) (OXB’s) strategic vision to come to further fruition through 2017/18 with both the potential approval of Novartis’s CTL019 in the US by year end and the possible spin-out/out-licensing of its priority development pipeline assets (OXB-102, OXB-202, and OXB-302). Full year 2016 results revealed robust growth in partnering revenues and 2017 will benefit from lower R&D expenses; we forecast a narrowing of EBITDA loss for the year. The net £17.5m equity fundraising and the Oberland debt facility has extended the current cash runway to 2019, aided by the reduction in near-term R&D; further funding and value may arise from additional manufacturing or IP licensing deals. Our revised valuation for OXB is £208.5m (6.75p/share).
CTL019 next steps: Potential for US launch in 2017
The global registration trial (ELIANA) of CTL019 in paediatric r/r B-cell acute lymphoblastic leukaemia (B-ALL) demonstrated overwhelming efficacy; 82% of patients treated achieved a complete remission or complete remission with incomplete blood count recovery. FDA have accepted Novartis’ Biologics License Application (BLA) and granted priority review for CTL019. We assume launch in 2017 (US) and Europe (2018) to directly benefit OXB, given its lentiviral technology remains vital to the manufacture of CTL019. We currently assume that a substantial portion of the $76m receivable from Novartis under the October 2014 contract has been delivered by mid-2017.
To read the entire report Please click on the pdf File Below
Oxford Biomedica - CTL019 And Product Out-Licensing To Drive 2017
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.